4//SEC Filing
Kirn David 4
Accession 0000950170-24-002945
CIK 0001650648other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 4:19 PM ET
Size
13.2 KB
Accession
0000950170-24-002945
Insider Transaction Report
Form 4
Kirn David
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2023-12-15$17.27/sh−28,632$494,432→ 1,230,521 total - Sale
Common Stock
2023-12-18$18.13/sh−4,702$85,243→ 1,225,819 total - Sale
Common Stock
2024-01-04$20.31/sh−40,732$827,202→ 1,185,087 total - Sale
Common Stock
2024-01-05$20.11/sh−133$2,674→ 1,156,850 total - Sale
Common Stock
2024-01-05$19.56/sh−28,104$549,804→ 1,156,983 total
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
- [F2]The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
4D Molecular Therapeutics, Inc.
CIK 0001650648
Entity typeother
Related Parties
1- filerCIK 0001834021
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 4:19 PM ET
- Size
- 13.2 KB